There is nothing more irksome than companies not meeting their own deadlines. I think AMBS is a bare bone operation at the moment and communicating to common share holders is far down on the level of importance. It seems to me the PRs are mostly designed to the benefit of prospective investors. Having said that, I am encouraged by recent business developments and executions; also hopeful AMBS has continued working on multiple fronts, very little sign of dilution and the stock has held up remarkably stable.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links